Press Releases
sterna biologicals commences phase I clinical trial of first-in-class DNAzyme-based GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma
Download this release as PDFMarburg, Germany, 07 November 2011 – sterna biologicals GmbH & Co. KG ("sterna biologicals") is pleased to announce first dosing of its novel inhaled GATA-3 antagonist SB010 for the treatment of moderate to severe Th2-driven asthma in a phase I clinical trial. The trial is a randomised, double-blind, placebo-controlled assessment of safety and tolerability of single ascending doses of SB010 in 48 male subjects conducted by CRS Clinical Research Services Mannheim GmbH in Mannheim, Germany.